Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Ontology highlight
ABSTRACT:
DISEASE(S): Sarcoma,Metastatic Solid Tumor,Colon Cancer,Melanoma,Advanced Solid Tumors,Soft Tissue Sarcoma,Carcinoma, Non-small-cell Lung,Lung Neoplasms,Cancer,Nonsmall Cell Lung Cancer
PROVIDER: 5280 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Background and study aims
Treatment in patients with advanced colorectal cancer, (CRC) non-small cell lung cancer (NSCLC) and soft tissue sarcoma (STS) represent a significant unmet need. Local thermal ablation of tumor tissue using techniques such as radiofrequency ablation (RFA) or stereotactic radiotherapy is an established treatment option for different tumors, in particular, CRC and NSCLC. There is strong nonclinical and early clinical evidence that combining thermal ablation with the investigational product, 1.0% IP-001 for Injection might be able to turn ‘cold’ tumors into ‘hot’ tumors, inducing a long-term systemic immune response mediated by the patient’s immunological defense system against any remaining tumor cells both at the site of the ablation treatment and those that are outside or distant from the treated area (known as the abscopal effect).
The 2 components of treatment play unique roles in inducing an antitumor immune response:
1. During thermal ablation, treated tumor undergoes immunogenic cell death via a well-defined heat gradient
2. Adding 1.0% IP-001 for Injection elicits a tumor-specific adaptive immune response
As a result, it is hypothesized that ablation + IP-001 can be deployed against a wide variety of tumor types to induce customized immune activation against a patient’s own, unique cancer.
Who can participate?
Adult patients with confirmed CRC, NSCLC, or STS
What does the study involve?
In this study, a solid tumor will first be thermally ablated by a standard ablation modality, and then 1.0% IP-001 for Injection will be injected into the area of the ablated tumor. Patients can be treated every 6 weeks for up to 4 treatments with RFA + 1.0% IP-001 for Injection.
| 2761466 | ecrin-mdr-crc
Project description:To determine the effect on gene expression of intratumoral injection of the Toll-like receptor agonist CpG1826. MC38 colon cancer cells were injected subcutaneously into C57BL/6 mice and allowed to establish until ~40 mm2.
2009-09-23 | GSE18203 | GEO
Project description:The goal of this study was to investigate the effect of intratumoral injection of GLA-SE, a TLR4 agonist in stable emulsion (SE), in Balb/c mice with established A20 lymphoma.
2020-08-04 | GSE150457 | GEO
Project description:We examined the effects of ICG-001 on gene expression in Mel202 uveal melanoma (UM) cells. ICG-001 exerted strong antiproliferative activity against UM cells, leading to cell cycle arrest, apoptosis, and inhibition of migration. Global gene expression profiling revealed strong suppression of genes associated with cell cycle proliferation, DNA replication, and G1/S transition. Gene set enrichment analysis revealed that ICG-001 suppressed Wnt, mTOR, and MAPK signaling. Strikingly, ICG-001 suppressed the expression of genes associated with UM aggressiveness, including CDH1, CITED1, EMP1, EMP3, SDCBP, and SPARC. Notably, the transcriptomic footprint of ICG-001, when applied to a UM patient dataset, was associated with better clinical outcome. Lastly, ICG-001 exerted anticancer activity against a UM tumor xenograft in mice.
2020-04-28 | GSE149417 | GEO
Project description:The CREB binding protein inhibitor ICG-001 suppresses pancreatic cancer growth We used microarrays to detail global gene expression changes in the pancreatic cancer cell line AsPC1 following treatment with ICG-001 or siRNA-mediated knockdown of CTNNB1 (beta-catenin) AsPC1 cells were treated with 10uM ICG-001 or vehicle control (DMSO) for either 6 hours or 24 hours. AsPC-1 cells were also separately transfected with 20nM control siRNA or CTNNB1 siRNA for 48 hours. RNA was extracted at these time points for hybridization to Affymetrix microarrays
2014-07-15 | E-GEOD-57728 | biostudies-arrayexpress
Project description:The CREB binding protein inhibitor ICG-001 suppresses pancreatic cancer growth We used microarrays to detail global gene expression changes in the pancreatic cancer cell line AsPC1 following treatment with ICG-001 or siRNA-mediated knockdown of CTNNB1 (beta-catenin)
2014-07-15 | GSE57728 | GEO
Project description:To inhibitors for ADAR1 and a strong rationale for the development of ADAR1 p150 inhibitors for cancer immunotherapy Here, we describe AVA-ADR-001, a potential first-in-class small molecule inhibitor of ADAR1 p150 targeting the Z alpha domain. AVA-ADR-001 binds specifically to the Z alpha domain of ADAR1 p150 as confirmed by fluorescence spectroscopy and showed significant interferon induction in THP1 macrophages, which have high ADAR1 p150 expression compared with monocytes. Proteomics and transcriptomics analysis revealed significant upregulation of interferon signaling upon treatment with AVA-ADR -001. Interestingly, activation of interferon signaling resulted in AVA-ADR-001 induced cell killing in ADAR1-independent cell lines. In addition, treatment with AVA-ADR -001 resulted in significant activation of PKR, which may explain the decreased cell proliferation. Finally, AVA-ADR-001 showed superior anti-tumor efficacy compared to anti-PD1 in an in vivo tumor efficacy study and has a moderately synergistic effect when combined. Overall, this study reveals that ADAR1 p150 inhibition by AVA-ADR-001 exerts a multipronged impact on anti-tumor efficacy mediated by immune cells, accumulation of interferons and activation of PKR, resulting in protein translation inhibition and cell proliferation arrest.
2023-04-17 | GSE229503 | GEO
Project description:RRx-001 (also known as ABDNAZ, 1-bromoacetyl-3,3-dinitroazetidine) is a novel aerospace-derived compound currently under investigation in several ongoing Phase II studies. In a Phase I trial, it demonstrated anti-cancer activity and evidence of resensitization to formerly effective therapies in heavily pre-treated patients with relapsed/refractory solid tumors. With a pharmacologically unprecedented dinitroazetidine scaffold, RRx-001 generates reactive oxygen and nitrogen species (ROS and RNS) and nitric oxide (NO), elicits changes in intracellular redox status, modulates tumor blood flow, hypoxia and vascular function and triggers apoptosis in cancer cells. Here, the effect of RRx-001 on the epigenome of SCC VII cancer cells was investigated. RRx-001 at 0.5 and 2 μM significantly decreased global DNA methylation, i.e., 5-methylcytosine levels, in SCC VII cells determined by analysis with an enzyme-linked immunosorbent assay (ELISA). Consistently, 0.5-5 μM RRx-001 significantly decreased Dnmt1 and Dnmt3a protein expression determined using Western blot in a dose- and time-dependent manner. In addition, global methylation profiling identified differentially methylated genes in SCC VII cells treated with 0.5, 2, and 5 μM RRx-001 compared to control cells. Twenty-three target sites were hypomethylated and 22 hypermethylated by >10% in the presence of at least two different concentrations of RRx-001. Moreover, RRx-001 at 2 μM significantly increased global acetylated histone H3 and H4 levels in SCC VII cells after 24 hour treatment determined by a fluorometric assay, suggesting that RRx-001 regulates global acetylation in cancer cells. These results demonstrate that, in contrast to the traditional “one drug one target” paradigm, RRx-001 has multi(epi)target features, which contribute to its anti-cancer activity and may rationalize the resensitization to previously effective therapies observed in clinical trials and serve as a unifying mechanism for its anticancer activity.
2016-12-31 | GSE74797 | GEO
Project description:UFH-001 cells, a newly isolated breast cancer line, have an STR profile that is most similar to that of the control MCF10A cells. Yet, the UFH-001 line is tumor forming with a triple negative phenotype. These cells have a unique transcriptome profile associated numerous breast cancer marker genes. We used microarrays to detail the global programme of gene expression underlying the metastatic behavior of the UFH-001 cells compared to the MCF10A cells.
2018-06-01 | GSE107209 | GEO